Thymic epithelial tumors are rare cancers originating from the thymus, with an annual incidence of 0.13 per 100,000 persons.
Therefore, the standard of care was approved primarily based on the results of single-arm phase II trials.
If the disease is resectable and localized, a multidisciplinary treatment combining surgical resection, radiotherapy, and pharmacotherapy should be considered.
Pharmacotherapy is the mainstay of treatment for metastatic and recurrent diseases.
